Therapeutic Strategy: We mainly focus on small chemical compounds obtained by combinatorial chemistry and selected using functional assays that are relevant to the pathogenic events in MS and other neurological diseases.
System Biology Drug Discovery: We combine current biomedical knowledge with a systems approach (network theory, non-linear dynamics and computational tools) to identify the best therapeutic targets, and to predict combination therapies and identify side-effects in advance.
Modelling brain diseases: given the well-known limitations of individual animal models for brain diseases, we combine the use of models in different rodent strains (e.g. Experimental Autoimmune Encephalomyelitis –EAE- for multiple sclerosis) and those using different antigens, with in vitro models (organotypic culture, cell culture) and ex-vivo assays (e.g. immune assays using PBMC from patients and controls).